DOCKET NO: 278868US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

NOBUAKI ETO, ET AL. : EXAMINER: ROBINSON, BINTA M.

SERIAL NO: 10/550,857 :

FILED: APRIL 10, 2006 : GROUP ART UNIT: 1625

FOR: COMPOUND INHIBITING IN VIVO :

PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME

RESPONSE TO THE REQUIREMENT FOR RESTRICTION

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Requirement for Restriction mailed October 21, 2008, Applicants elect, without traverse, Group I: Claims 1-76 drawn to a product. As the species, Applicants elect Compound 863, 3 {[(2-diethylamino-ethyl)-methyl amino]-methyl}-*N*-[2,4-methoxy-benzylidene-hydrazino carbonyl -4-piperdin-1-yl-phenyl]-benzamide, which can be found on pages 422 and 519 of the specification. The claims readable on this election include Claims 1-76 with the exception of Claims 17-23, 53-55 and 59-65.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 06/04)

James H. Kneb